

## Glucose-Responsive Nanoparticles for Rapid and Extended Self-Regulated Insulin Delivery

Lisa R. Volpatti, Morgan A. Matranga, Abel B. Cortinas, Derfogail Delcassian, Kevin B. Daniel, Robert Langer, and Daniel G. Anderson

ACS Nano, **Just Accepted Manuscript** • DOI: 10.1021/acsnano.9b06395 • Publication Date (Web): 25 Nov 2019

Downloaded from [pubs.acs.org](https://pubs.acs.org) on December 2, 2019

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Glucose-Responsive Nanoparticles for Rapid and Extended Self-Regulated Insulin Delivery

*Lisa R. Volpatti,<sup>†, ‡</sup> Morgan A. Matranga,<sup>†</sup> Abel B. Cortinas,<sup>†, ‡</sup> Derfogail Delcassian,<sup>‡, §, ⊥</sup> Kevin B. Daniel,<sup>‡</sup> Robert Langer,<sup>†, ‡, §, ∇</sup> Daniel G. Anderson<sup>†, ‡, §, ∇\*</sup>*

<sup>†</sup> Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>‡</sup> David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>§</sup> Department of Anesthesiology, Boston Children's Hospital, Boston, MA 02115, USA

<sup>⊥</sup> Regenerative Medicine and Cellular Therapies, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK

<sup>∇</sup> Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

\*E-mail: [dgander@mit.edu](mailto:dgander@mit.edu)

## Abstract

To mimic native insulin activity, materials have been developed that encapsulate insulin, glucose oxidase, and catalase for glucose-responsive insulin delivery. A major challenge, however, has been achieving the desired kinetics of both rapid and extended release. Here, we tune insulin release profiles from polymeric nanoparticles by altering the degree of modification of acid-degradable, acetalated-dextran polymers. Nanoparticles synthesized from dextran with a high acyclic acetal content (94% of residues) show rapid release kinetics, while nanoparticles from dextran with a high cyclic acetal content (71% of residues) release insulin more slowly. Thus, co-formulation of these two materials affords both rapid and extended glucose-responsive insulin delivery. *In vivo* analyses using both streptozotocin-induced type 1 diabetic and healthy mouse models indicate that this delivery system has the ability to respond to glucose on a therapeutically relevant timescale. Importantly, the concentration of human insulin in mouse serum is enhanced more than 3-fold with elevated glucose levels, providing direct evidence of glucose-responsiveness in animals. We further show that a single subcutaneous injection provides 16 h of glycemic control in diabetic mice. We believe the nanoparticle formulations developed here may provide a generalized strategy for the development of glucose-responsive insulin delivery systems.

## Keywords

stimuli-responsive, biomaterials, drug delivery, nanoparticles, insulin, diabetes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
Diabetes mellitus is a class of diseases in which the body either does not produce (Type 1) or is insensitive to (Type 2) insulin, resulting in poorly controlled blood glucose levels.<sup>1</sup> Chronic hyperglycemia often leads to severe complications including retinopathy, cardiovascular disease, kidney failure, and cancer.<sup>1,2</sup> These complications may be limited in both Type 1 and many Type 2 diabetic patients with intensive insulin therapy, requiring multiple daily blood glucose measurements and insulin injections.<sup>3,4</sup> However, intensive therapy results in decreased patient compliance<sup>5,6</sup> and increased risk of hypoglycemia,<sup>7</sup> which can cause brain damage, seizures, loss of consciousness, or death.<sup>8,9</sup> Current insulins on the market may be classified as rapid acting, short acting, intermediate acting, or long acting.<sup>10-12</sup> However, no available formulations dynamically regulate insulin release in response to glucose levels according to individual patient needs. Therefore, self-regulated delivery of insulin that mimics native insulin production in a healthy pancreas has the potential to improve diabetes therapy. Insulin pump therapy has been developed to offer continuous glucose sensing coupled with insulin infusions;<sup>13,14</sup> however, many challenges remain including inaccuracies of continuous glucose sensors and lags in signal feedback.<sup>15-17</sup>

35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
An alternative approach is to deliver insulin with glucose-responsive biomaterials.<sup>18</sup> Recently, formulations have been developed that can respond to local changes in glucose with an associated change in insulin release rates.<sup>19</sup> Glucose detection in these systems is often mediated by the covalent attachment of a glucose-sensing moiety, namely a boronic acid, or incorporation of the enzyme glucose oxidase (GOx).<sup>20</sup> GOx catalyzes the oxidation of glucose to gluconolactone which is readily hydrolyzed to gluconic acid and has been used in combination with pH-sensitive biomaterials as glucose-responsive systems.<sup>21-23</sup> Catalase is commonly co-encapsulated with the GOx to disproportionate the reactive hydrogen peroxide byproduct and regenerate oxygen needed for the enzymatic conversion of glucose.<sup>24-26</sup> Since the accumulation of gluconic acid must first

1  
2  
3 overcome physiological buffering effects to reduce the pH of the surrounding microenvironment,  
4 these formulations often suffer from significant delays in the glucose-responsive release of  
5 appreciable amounts of insulin. To overcome this challenge, materials have been developed that  
6 more rapidly respond to the hypoxic environment or the hydrogen peroxide generated by the  
7 enzymatic oxidation of glucose.<sup>27-29</sup> However, due to the rapid release of encapsulated insulin,  
8 multiple doses are required to provide glycemic control *in vivo* for up to 10 h.<sup>27,29</sup>  
9

10  
11 To develop a system that responds on a therapeutically relevant timescale and can afford  
12 sustained glucose-responsive insulin delivery *in vivo*, we co-formulate rapid-release and  
13 prolonged-release acetalated dextran nanoparticles (Ac-dex NPs) encapsulating GOx, catalase,  
14 and insulin. We found that this combination of two types of materials is required to achieve the  
15 desired kinetics of both rapid-onset and extended release of insulin. Analyses in both healthy and  
16 diabetic mouse models show direct evidence of glucose-responsiveness *in vivo*, rapid glycemic  
17 control, and prolonged normoglycemia for 16 hours with a single subcutaneous injection in a  
18 diabetic mouse model.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **Results and Discussion**

### 39 **Preparation and Characterization of Ac-Dex Nanoparticles**

40  
41 Ac-dex is a pH-responsive polymer synthesized by reacting dextran with methoxypropene  
42 (S1).<sup>30,31</sup> Acyclic acetal modifications are formed first which then react with neighboring hydroxyl  
43 groups to form the more stable cyclic modifications. The acetal groups are cleaved in the presence  
44 of acid to reform the native, soluble polysaccharide. Following acetal cleavage, the resultant  
45 degradation products are analyzed by <sup>1</sup>H NMR to determine the amount of each type of  
46 modification (Fig. S2). Polymers with high acyclic acetal content degrade quickly while those with  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 high cyclic acetal content have longer half-lives. A combination of nanoparticles made from these  
4  
5  
6 polymers can therefore provide both rapid and prolonged release kinetics (Fig. 1a).

7  
8 In order to develop a system with desired release kinetics, we synthesized several  
9  
10 derivatized dextran polymers with varying degrees of modification. For reaction times between 10  
11  
12 and 60 min, the fraction of acyclic modifications decreases as more cyclic modifications are  
13  
14 formed. The percentage of residues containing a single cyclic modification increases from 55%  
15  
16 (C55) after 10 min of reaction to 83% (C83) after 60 min while the percentage of acyclic  
17  
18 modifications decreases from 94% to 83% (Figure S3). To probe the kinetics of acetal cleavage,  
19  
20 nanoparticles with a consistent diameter ( $252 \pm 25$  nm, Figure S4a) were synthesized from a range  
21  
22 of polymers and incubated in either acetate buffer (pH 4.7) or phosphate buffered saline (PBS, pH  
23  
24 7.4) at 37 °C with agitation. The amount of soluble dextran in the supernatant was measured over  
25  
26 time to represent polymer degradation. Nanoparticles synthesized from the least modified polymer  
27  
28 (C55NPs) were > 80% degraded within the first hour, while those from polymers with increasing  
29  
30 percentage of modifications were more stable in acidic solution (Figure 1b). Notably, nanoparticles  
31  
32 from the two least modified polymers showed minimal degradation upon incubation at pH 7.4 for  
33  
34  
35  
36  
37  
38 24 hours (Figure 1b).

39  
40 We next synthesized NPs ( $274 \pm 22$  nm, Figure S4b) encapsulating insulin, GOx, and  
41  
42 catalase. GOx converts glucose to gluconolactone which is rapidly hydrolyzed into gluconic acid  
43  
44 and reduces the pH of the microenvironment when glucose levels are high. The acetal groups of  
45  
46 the modified dextran are subsequently cleaved, solubilizing the NPs and releasing the encapsulated  
47  
48 insulin on-demand (Figure 1c). Thus, locally regulating the pH near the NPs allows for the  
49  
50 controlled release of insulin. To better understand the process of degradation, C55NPs were  
51  
52 exposed to acidic solution, and their size was monitored by dynamic light scattering (DLS) over  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 time (Fig S4c). The NPs reduced in size over the first hour reaching 67% of their original diameter  
4  
5 before becoming undetectable by DLS (Figure 1d), suggesting that they degrade at least partially  
6  
7 by surface erosion. Cryo-transmission electron micrographs (TEM) show spherical NPs with  
8  
9 diameters consistent with DLS measurements at time 0 (inset, Figure 1d; Figure S5).  
10  
11

12 The insulin loading of the C55NPs is 8.3% by mass, nearly double the amount in the  
13  
14 C71NPs and over 6 times that in the C78NPs, which suggests that the insulin loading capacity  
15  
16 decreases exponentially with acetalation reaction time (Figure S6a). The C55NPs contain ~ 1 U  
17  
18 GOx / mg NP, and the loading of GOx similarly decreases with percent modification (Figure S6b).  
19  
20 The increased hydrophobicity of highly modified dextran may limit the amount of total protein  
21  
22 loading. Thus, by varying the percent modification of the dextran, we can systematically alter the  
23  
24 material properties to tune both the release profile and the protein loading efficiency.  
25  
26  
27  
28  
29  
30

### 31 **Insulin Release Kinetics**

32  
33 To determine the kinetics of insulin release, protein-encapsulated NPs were incubated in either  
34  
35 acetate buffer or PBS (20 mg/mL). The resultant release profiles closely follow the degradation  
36  
37 profiles for both the C55NPs and C71NPs (Figure 2a). The release kinetics were then studied in  
38  
39 response to elevated (400 mg/dL) or physiological (100 mg/dL) glucose concentrations. The  
40  
41 C55NPs show a rapid response to elevated glucose levels with virtually all insulin released after 2  
42  
43 hours; however, they are completely degraded under physiological glucose concentrations after 4  
44  
45 hours of incubation (Figure 2b). The C71NPs, on the other hand, have a delayed onset of release  
46  
47 (after 2 hours) with a prolonged release of insulin under lower glucose conditions (up to 6 hours,  
48  
49 Figure 2b). Based on these results, we hypothesized that a mixture of NPs could provide fast- and  
50  
51 long-acting delivery options.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A co-formulation containing equal parts by mass of C55NPs (rapid-release) and C71NPs  
4 (extended-release) shows two regimes of release in response to an acidic environment (Figure 2c).  
5  
6 The same formulation affords a rapid onset of release in elevated glucose conditions with a more  
7  
8 prolonged release under physiological concentrations of glucose (Figure 2d). The pH profiles are  
9  
10 similar for the C55NPs alone, the C71NPs alone, or a mixture of the two (Figure S7). In high  
11  
12 glucose conditions, a period of  $\sim 2$  h is required to overcome the buffering effects of the solution  
13  
14 and decrease the pH below 5 accounting for the delayed onset of insulin release. In low glucose  
15  
16 conditions, the pH reaches 5 after  $\sim 4$  h. Therefore, the differences in release kinetics may be  
17  
18 attributed to the prolonged degradation of the more highly modified polymeric nanoparticles. At a  
19  
20 lower concentration of NPs (10 mg/mL), there is a greater distinction in the onset of insulin release  
21  
22 across a range of glucose concentrations (Figure S8a). Furthermore, insulin is released in less than  
23  
24 an hour when NPs are first incubated in physiological glucose conditions before being exposed to  
25  
26 elevated glucose (Figure S8b).  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Activity and Biocompatibility**

36  
37 After analyzing the release kinetics in response to varying glucose concentrations, we then  
38 confirmed that the released insulin retains its structure and function. Insulin-encapsulated C55NPs  
39  
40 were incubated at 37 °C with agitation in buffer containing trypsin (0.025%) for 24 h. Circular  
41  
42 dichroism (CD) spectra of the released insulin shows excellent agreement with that of fresh insulin  
43  
44 (Figure 2e), confirming its protection from proteolytic degradation and retention of its  
45  
46 characteristic alpha helix structure. To show that insulin remains bioactive after formulation and  
47  
48 release, a cell-based assay was performed to quantify the amount of AKT phosphorylation caused  
49  
50 by the activation of the insulin receptor. The resultant dose-response curves (Figure S9) were used  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 to calculate the  $EC_{50}$  of the sample. No significant differences in activity are observed between  
4  
5 fresh insulin and insulin that has been incubated in NPs up to 24 h (Figure 2f). These results suggest  
6  
7 that insulin is unaltered during NP processing, incubation, and release. Furthermore, NP  
8  
9 components show minimal toxicity to these cells at the concentrations tested. To further probe  
10  
11 cytotoxicity of intact NPs, we performed a hemolysis assay for blood compatibility (Figure S10).  
12  
13 Hemolysis of erythrocytes was < 1% for relevant doses of NPs when compared to PBS (negative  
14  
15 control) and 1% Triton X-100 (positive control), providing further evidence of their  
16  
17 biocompatibility.  
18  
19  
20

21  
22 Before determining the efficacy of the NPs *in vivo*, we tested whether they remain at the  
23  
24 site of injection after subcutaneous (s.c.) administration in a mouse model. To study particle  
25  
26 migration, we formulated Ac-dex NPs without proteins encapsulating a fluorescently labeled  
27  
28 dextran (AF-680). We then s.c. injected these NPs into immunocompetent, hairless, albino SKH1E  
29  
30 mice and quantified their fluorescence over time using an *in vivo* imaging system (IVIS; Figure  
31  
32 S11a). Since these NPs do not contain the glucose-sensing enzyme, they are not expected to rapidly  
33  
34 degrade and release their cargo, and the decrease in fluorescence can largely be attributed to  
35  
36 particle migration. On day 3, the total fluorescence is on average 76.5% that of day 1, suggesting  
37  
38 limited particle migration away from the site of injection during the time of therapeutic effect  
39  
40 (Figure S11b).  
41  
42  
43

44  
45 Our Ac-dex NPs are polysaccharide based. As some types of foreign polysaccharides have  
46  
47 been shown to cause inflammation when implanted subcutaneously,<sup>32</sup> we next evaluated the  
48  
49 potential of an inflammatory response to the NPs. Systemic inflammation was assessed by  
50  
51 measuring serum cytokine levels at 6 and 24 h post s.c. NP administration. For cytokine analysis,  
52  
53 serum from mice treated with empty NPs or NPs containing insulin and enzymes (5 mg NPs/kg)  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 was compared to serum from control mice treated with saline (negative control) or  
4 lipopolysaccharide (LPS, 2 mg/kg, positive control). Pro-inflammatory cytokines interleukin-1 $\beta$   
5 (IL-1 $\beta$ ), IL-6, IL-12, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) were significantly elevated at 6 and 24  
6 h in mice post-treatment with the inflammatory polysaccharide LPS compared to saline-treated  
7 controls (Figure 3a-d). Granulocyte-macrophage colony-stimulating factor (GM-CSF) was  
8 significantly elevated in LPS-treated mice at 6 but not 24 h post-administration (Figure S12a).  
9 These cytokines demonstrated a greater than 1.5 fold increase in circulating systemic levels at 6  
10 hours following s.c. administration of LPS (IL-1 $\beta$ : 1.8, IL-6: 19.1, IL-12: 3.9, TNF- $\alpha$ : 6.7, GM-  
11 CSF: 1.7 fold increase). In contrast, cytokine levels from animals treated with empty NPs or NPs  
12 containing insulin and enzymes were not significantly different from animals treated with saline,  
13 suggesting our NPs do not induce systemic inflammation (Figure 3a-d). We also analyzed levels  
14 of circulating cytokines IL-2, IL-4, IL-5, IL-10, and interferon  $\gamma$  (IFN $\gamma$ ). These cytokines were not  
15 elevated in response to LPS or administration of empty and insulin/enzyme-encapsulated NPs  
16 indicating that the Ac-dex system described is systemically non-inflammatory and non-  
17 immunogenic (Figure S12b).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37  
38 Next, local inflammation was assessed through histological analysis of skin biopsies at 1,  
39 7 or 28 days post subcutaneous administration of empty nanoparticles or a PBS control. The  
40 biopsies were processed for histological analysis and stained with hematoxylin and eosin (H&E).  
41 The presence of neutrophils in the H&E-stained histological images indicated that 4/5 mice  
42 exhibited a local inflammatory response 1 day after NP injection (Figure S13). After 1 week, 2/5  
43 mice had few macrophages present (Figure S13). After 1 month there were no signs of  
44 inflammation in any of the 5 mice, and the H&E-stained histological images were comparable to  
45 those from the saline-treated mice (Figure 3e-f). These results are consistent with previous reports  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of *in vivo* biocompatibility of Ac-dex<sup>33</sup> and suggest that Ac-dex NPs do not cause a severe or  
4 prolonged local inflammatory response when s.c. injected in mice.  
5  
6  
7  
8  
9

### 10 ***In Vivo* Glycemic Control**

11  
12 To evaluate the ability of the nanoparticles to provide glucose-responsive glycemic control *in vivo*,  
13 we employed both streptozotocin (STZ)-induced type 1 diabetic mouse and healthy mouse models.  
14 Fasted diabetic mice were subcutaneously injected with a dose of 3 IU/kg naked insulin, a co-  
15 formulation of C55NPs and C71NPs at an insulin dose of 14.4 IU/kg (0.5 mg/kg), or a co-  
16 formulation of empty NPs, and their blood glucose (BG) levels were monitored over time (Figure  
17 4a). The BGs of the 14.4 IU/kg NPs group were reduced at virtually the same rate as those in the  
18 naked insulin group, indicating a rapid onset of insulin release in elevated glucose conditions *in*  
19 *vivo*. To test if this initial reduction in BG levels was due to nonspecific burst release, NPs were  
20 incubated for an hour *in vitro* and transferred to fresh buffer prior to injection (Figure S14a). The  
21 resultant BG profile and area under the curve (AUC) of the pre-incubated NPs was similar to that  
22 of directly injected NPs (Figure S14b), suggesting that this initial rapid release is specific to the *in*  
23 *vivo* environment.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Diabetic mice were administered an intraperitoneal glucose tolerance test (GTT, 1.5 g/kg)  
41 after 3 h to test the efficacy of the NPs in responding to a glucose challenge (Figure 4a). The mice  
42 receiving 3 IU/kg naked insulin returned to their initial hyperglycemic state directly following the  
43 GTT. In contrast, the NP group successfully regained glycemic control after an initial spike in BG  
44 levels and maintained BGs in the normoglycemic range (70 – 200 mg/dL) following 4 additional  
45 GTTs, thus providing 16 h of glycemic control with a single dose. The mice returned  
46 hyperglycemic 2 d post-injection, indicating the potential of NPs as a once-daily treatment (Figure  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 S15). The AUCs following 9 h and 2 GTTs show that NP doses of 5, 9, or 14.4 IU/kg insulin  
4 provide significantly enhanced glycemic control compared to 3 IU/kg naked insulin (Figure 4b,  
5  
6 S16).  
7  
8  
9

10 NPs were next s.c. administered to healthy mice to determine their *in vivo* response to  
11 normoglycemic conditions (Figure 4c). While mice receiving 3 IU/kg naked insulin experienced  
12 hypoglycemia, defined as having an average blood sugar concentration less than 70 mg/dL, the  
13 NP group, receiving almost 5 times the dose of insulin, remained in the normoglycemic range. The  
14 area above the curve (AAC) and below the initial BG value for the first 2.5 h is used to quantify  
15 the hypoglycemic effect. With this metric, NP doses of 5, 9, or 14.4 IU/kg insulin provide  
16 significantly reduced risk of a hypoglycemic event compared to 3 IU/kg naked insulin (Figure 4d,  
17 S17). Thus, doses between 5 and 14.4 IU/kg NPs enhance glycemic control in diabetic mice and  
18 reduce the hypoglycemic effect in healthy mice compared to a single dose of 3 IU/kg naked insulin.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Since healthy mice have lower fasting BG levels than diabetic mice, they may initially  
32 experience hypoglycemia more rapidly. However, they may also respond to the insulin more  
33 rapidly by secreting counterregulatory hormones such as glucagon. Therefore, we also examined  
34 the potential for hypoglycemia in a diabetic mouse model. Mice receiving 9 IU/kg NPs were  
35 divided into 3 groups and administered i) a 1.5 g/kg GTT at 3 h and a 2 g/kg GTT at 6 h, ii) a 2  
36 g/kg GTT at 6 h alone, or iii) no GTTs over the 8 h study (Figure 5a). Different GTT doses were  
37 given to represent variability in glucose intake throughout the day. AUCs for groups (ii) and (iii)  
38 were not significantly different than that of group (i) (Figure 5b), and the average BGs of each  
39 group remained above 70 mg/dL for the duration of the study. These results indicate that a dose of  
40 9 IU/kg NPs is able to attain tight glycemic control despite small differences in glucose intake and  
41 poses limited risk of hypoglycemia under these conditions in diabetic mice.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To distinguish between glucose-responsive and non-responsive insulin release, fasted  
4 diabetic mice were administered nanoparticles containing enzymes and insulin (NPs),  
5 nanoparticles without enzymes (NPs (– Enzymes)), or nanoparticles without insulin (NPs (–  
6 Insulin)). While the *in vitro* data suggest NPs will be glucose-responsive *in vivo*, NPs(– Enzymes)  
7 are expected to slowly release insulin over time, representing basal insulin delivery. Following a  
8 3 g/kg GTT 2 h post-injection, the average BG of all groups rises above 400 mg/dL within 30 min.  
9  
10 After 30 min at this elevated BG level, the NP group reduces the BGs over the next 2 h and is the  
11 only group with an average BG in the normoglycemic range at the end of the 5 h study (Figure  
12 5c). These kinetics are slightly delayed compared to the rapid initial BG reduction which may  
13 have resulted from a larger release of insulin upon initial exposure to high glucose concentrations.  
14  
15 Nevertheless, the NPs begin to reduce the BG levels 1 h after bolus glucose administration and are  
16 ultimately able to regain glycemic control. These results suggest that all components of the  
17 nanoparticle are necessary to produce consistent glycemic control with significantly reduced  
18 AUCs (Figure 5d).

19  
20  
21 To further probe the difference between basal and glucose-responsive insulin, we next  
22 evaluated the BG levels of diabetic mice in response to equivalent doses (5 IU/kg) of NPs, a long-  
23 acting acylated analog of insulin (commercially known as insulin detemir),<sup>34,35</sup> and naked insulin  
24 (Figure 5e). Compared to NPs, naked insulin initially reduces BGs more rapidly at this dose, as  
25 shown by a significantly decreased AUC for the first 2.5 h following administration (Figure 5f).  
26  
27 However, the NP group is the only group with average BGs < 200 mg/dL following either of the  
28 1.5 g/kg GTTs at 3 h and 6 h (Figure 5e). Moreover, for the time interval between 6 – 9 h, the  
29 long-acting insulin and naked insulin groups both have significantly higher AUCs than the NP  
30 group (Figure 5f). Therefore, for the same dose of insulin (5 IU/kg), glucose-responsive NPs

1  
2  
3 provide better extended glycemic control compared to long-acting basal or naked insulin  
4  
5 treatments.  
6  
7  
8  
9

### 10 **Glucose-Responsive Insulin Release *In Vivo***

11  
12 To provide direct evidence of the translation of glucose-responsive delivery *in vivo*, we conducted  
13  
14 time course measurements of serum human insulin concentrations in healthy and diabetic mice.  
15  
16 Healthy mice receiving NPs (– Enzymes) or NPs experienced similar low levels of serum insulin  
17  
18 (< 20  $\mu$ IU/mL) after 1 h (Figure 6a). This result corroborates our findings that the NPs do not  
19  
20 experience a large glucose-independent burst release of insulin. At the 1 h time point, the mice  
21  
22 were administered a GTT (3 g/kg), and the serum insulin concentration was measured after an  
23  
24 additional hour (2 h total). Mice injected with NPs (– Enzymes) and mice that did not receive a  
25  
26 GTT (NPs (– GTT)) had similar serum insulin levels at the 1 and 2 h time points. Conversely, there  
27  
28 was > 3-fold increase in the amount of serum insulin in the NPs group after the GTT. These results  
29  
30 indicate that there is limited basal insulin release with a spike in release in response to glucose and  
31  
32 both enzymes and elevated glucose concentrations are required for enhanced insulin release *in*  
33  
34 *vivo*. Serum insulin of mice injected with NPs (– Insulin) were mostly below the range of detection  
35  
36 both before and after the GTT, confirming that mouse insulin shows minimal cross reactivity with  
37  
38 the human insulin ELISA (ALPCO) used for analysis (Figure S18).  
39  
40  
41  
42  
43  
44

45 Human insulin in diabetic mouse serum was monitored over time to quantify glucose-  
46  
47 responsive insulin release in a diseased state. Serum insulin levels reach a maximum 1 h after  
48  
49 injection, followed by low levels of basal serum insulin until the concentrations modestly increase  
50  
51 immediately after a GTT at 6 h (Figure 6b). The relative heights of these peaks suggest that insulin  
52  
53 release is greatest upon first exposure of the NPs to glucose, consistent with the BG reduction rates  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 from Figure 6. Mice receiving NPs (– Enzymes) had low serum insulin concentrations for the  
4 duration of the study with no significant increase after the GTT (Figure S19a). Serum insulin  
5 concentrations are comparable in diabetic mice and healthy mice following the initial exposure of  
6 the NPs to elevated glucose levels, whether after administration or a glucose injection (Figure 6c).  
7  
8 In both cases, serum insulin concentrations are significantly higher in the NPs group compared to  
9 the NPs (– Enzymes) group (Figure 6c, S19b). These results support the conclusion that both  
10 enzymes and hyperglycemia are required for enhanced insulin release *in vivo*.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## 21 **Conclusion**

22  
23 Insulin adherence of Type 2 diabetic patients is low,<sup>36,37</sup> with at least 35% of patients reporting  
24 dosing omission or irregularities.<sup>38,39</sup> Inflexibility of scheduled insulin doses and interference with  
25 daily activities are commonly cited as contributing factors of non-adherence to prescribed insulin  
26 regimens.<sup>39-41</sup> A once-daily insulin injection with some flexibility of timing and dose is expected  
27 to increase patient adherence and improve quality of life of diabetic patients.<sup>6</sup> Furthermore,  
28 glucose-responsive insulin may have the additional therapeutic benefits of improved glycemic  
29 control by smoothing out the peaks and valleys associated with multiple self-administered doses  
30 of insulin and reduced risk of hypoglycemia corresponding to fewer visits to the emergency  
31 department.<sup>42</sup> While once-weekly therapies also show promise in improving patient adherence,  
32 there are additional safety risks associated with a much larger dose of insulin.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46  
47 In order for a glucose-responsive delivery system to be effective, the kinetics must be rapid  
48 to quickly counteract a spike in blood sugar. Here, we report an example of fine tuning insulin  
49 release kinetics from polymeric NPs in response to glucose by controlling the extent of polymer  
50 modification. We expect this approach to aid in the development of future glucose-responsive  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 insulin delivery systems based on GOx. Most commercial implantable continuous glucose  
4 monitoring systems employ GOx as a sensor.<sup>43,44</sup> A limitation of using GOx and catalase in an  
5 injectable delivery system, however, is their potential toxicity and immune response from repeated  
6 administrations. Therefore, to make steps toward the translation of GOx-based glucose-responsive  
7 insulin delivery, methods of physically isolating the enzymes or chemically shielding them from  
8 the immune system should be further investigated.

9  
10  
11 In summary, we have developed a co-formulation of rapid-release (55% cyclic  
12 modifications) and prolonged-release (71% cyclic modifications) acetalated-dextran nanoparticles  
13 encapsulating insulin and enzymes that enhances glucose-responsive delivery. Glucose-  
14 responsiveness is directly evidenced *in vivo* with an increase in serum insulin following a glucose  
15 challenge in both healthy and diabetic mice (Figure 6). A main advantage of these co-formulated  
16 NPs is their ability to reduce elevated blood glucose levels in a diabetic mouse model on a  
17 timescale comparable to that of naked insulin and provide sustained delivery to afford 16 h of  
18 glycemic control after five simulated meals. In addition to providing enhanced glycemic control  
19 relative to free insulin when comparing the same dose of 5 IU/kg, these co-formulated NPs also  
20 reduce the risk of hypoglycemia. Thus, the development and characterization of these co-  
21 formulated, glucose-responsive nanoparticles marks an important step in the advancement of self-  
22 regulated insulin delivery.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Experimental Section

### Materials/reagents

All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and cell culture reagents from Life Technologies (Carlsbad, CA) unless otherwise noted. Recombinant human insulin (Gibco™) was purchased from ThermoFisher Scientific (Waltham, MA). AlphaLISA SureFire ULTRA kits were purchased from Perkin-Elmer (Waltham, MA) to quantify AKT phosphorylation, and an insulin ELISA kit was purchased from ALPCO (Salem, NH) to measure serum insulin.

### Nanoparticle synthesis

Empty acetelated-dextran nanoparticles were prepared with a single-emulsion, solvent evaporation technique. Briefly, Ac-dex was dissolved in dichloromethane (DCM; 40 mg/mL) and added to a 3% poly(vinyl alcohol) (PVA) in PBS solution. This two-phase mixture was sonicated for 90 s (Q-500, QSonica, 65% amplitude) with 1 s pulse and immediately poured into a 0.3% PVA solution. After stirring for 2 h, the mixture was centrifuged (15 min, 8000 rcf; Avanti JXN-26, Beckman Coulter) and washed twice with basic water (pH 8) before lyophilization. To form protein encapsulated nanoparticles, insulin was dissolved in carbonate buffer (pH 9.5, 100 mg/mL) with or without GOx (168.1 units/mg, 15 mg/mL) and catalase ( $\geq 20,000$  units/mg, 2 mg/mL) and added to DCM containing Ac-dex (40 mg/mL). The mixture was sonicated, added to a 3% PVA solution, and sonicated a second time to form a double emulsion, which was processed in the same manner as the single-emulsion nanoparticles.

### **Nanoparticle characterization**

Nanoparticles were characterized by dynamic light scattering (DLS; Zetasizer Nano ZS, Malvern Instruments) and cryo-transmission electron microscopy (TEM, JEOL 2100F). Lyophilized nanoparticles were suspended in ultrapure water and filtered through 0.8  $\mu\text{m}$  membrane filters before analysis by DLS or cryo-TEM. To determine degradation kinetics, nanoparticles were suspended in acetate buffer, incubated in a 37  $^{\circ}\text{C}$  shaker, and analyzed at various time points (0, 15, 30, 45, 60 min).

### **Acetalated-dextran degradation analysis**

Empty Ac-dex nanoparticles were suspended in triplicate in acetate buffer (pH 4.7) or in PBS (pH 7.4) at 5 mg/mL and incubated at 37  $^{\circ}\text{C}$  on a shaker plate. At indicated time points, aliquots were withdrawn and centrifuged. The supernatants were removed and analyzed with a microplate bicinchoninic acid assay (BCA; Pierce) according to the manufacturer's protocol using a dextran standard. The absorbance was measured at 562 nm with a plate reader (Infinite M200, Tecan).

### ***In vitro* insulin release**

Nanoparticles containing insulin (5 mg/mL) or insulin and enzymes (10 mg/mL or 20 mg/mL) were suspended in triplicate in PBS alone or with the addition of 100 mg/dL or 400 mg/dL glucose and incubated at 37  $^{\circ}\text{C}$  with agitation. At indicated time points, aliquots were withdrawn and centrifuged. The supernatants were removed and protein content was analyzed with a Coomassie Plus protein assay (Pierce) according to the manufacturer's protocol.

### **Insulin structure**

Secondary structural motifs were elucidated using high-performance circular dichroism (CD). Nanoparticles containing insulin (2.5 mg/mL) were incubated in a 1:10 solution of 0.25% Trypsin-EDTA:PBS at 37 °C with agitation. After 24 h, the nanoparticles were washed thrice to remove the trypsin and degraded with HCl (pH 2). NaOH was used to return the pH to 7.4. This sample and fresh recombinant human insulin (200 µg/mL) were analyzed with a high-performance CD spectrometer (J-1500, JASCO Inc.) using a 0.1 cm pathlength cell.

### ***In vitro* activity**

The *in vitro* activity of released insulin was determined with a cellular AKT assay. To prepare for the AKT assay, C2C12 cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle medium (DMEM) containing L-glutamine, 4.5 g/L D-glucose, and 110 mg/L sodium pyruvate supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. Cells were seeded and incubated in 96-well plates at a density of 5,000 cells per well. After 24 h, the cells were washed twice with serum-free DMEM and incubated for 4 h. The media was then removed, and the cells were stimulated with insulin samples or controls for 30 min. The cells were then washed twice with cold Tris-buffered saline and lysed with cold Lysis Buffer (Perkin-Elmer) for 10 min. Concentrations of pAKT 1/2/3 (Ser473) and total AKT 1 in the cell lysates were determined with AlphaLISA SureFire ULTRA kits (Perkin-Elmer) according to the manufacturer's instructions. Data were analyzed using GraphPad Prism 6.0 and fit to four parameter dose-response curves to determine the EC<sub>50</sub> of each insulin sample.

### ***In vivo* glycemic control studies**

All animal protocols were approved by the MIT Committee on Animal Care, and animals were cared for under supervision of MIT's Division of Comparative Medicine. The safety and efficacy of Ac-dex nanoparticles were evaluated using healthy and diabetic C57BL/6 mice (Jackson Labs). To induce diabetes, adult male mice were injected with a single dose of 150 mg/kg streptozotocin. Groups of at least 4 mice were fasted for 12 h and subcutaneously injected with nanoparticles, long-acting insulin, or naked insulin. Their blood glucose levels were monitored every 30 min following injection with Clarity BG1000 Blood Glucose Meters. Glucose tolerance tests were performed by administering 1.5 – 3 g/kg glucose to the mice intraperitoneally. To measure serum insulin concentration, blood was collected by terminal cardiac punctures into serum gel microtubes (BD SST™ Microtainer). After centrifugation (5 min, 7000 rcf), serum was collected and analyzed immediately using an insulin ELISA kit (ALPCO) according to the manufacturer's instructions. Values below the standard curve are reported as less than or equal to 3  $\mu$ IU/mL, the limit of detection of the ELISA.

### **Inflammatory response characterization**

To quantify systemic cytokine concentration, 100  $\mu$ L of blood was collected from the saphenous vein of mice 6 h following administration of PBS, 2 mg/kg lipopolysaccharide (LPS), 5 mg/kg empty NPs, or 5 mg/kg NPs encapsulating insulin and enzymes in addition to naïve mice. Blood was collected into serum gel microtubes (BD SST™ Microtainer), centrifuged (5 min, 7000 rcf), and flash frozen until analysis. At 24 h, blood was collected by terminal cardiac punctures and processed similarly. Serum samples were analyzed using a mouse multiplex cytokine ELISA (Invitrogen, magnetic 10-plex: IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GMCSF, IFN $\gamma$ , and

1  
2  
3 TNF- $\alpha$ ) run on a Luminex 200 platform. Values below the standard curve are reported as less than  
4  
5 or equal the limit of detection of the assay. To characterize the local inflammatory response,  
6  
7 animals were euthanized at 1, 7, and 28 days following administration of 5 mg/kg empty NP or  
8  
9 PBS, and skin sections surrounding the injection site were biopsied with a 5 mm biopsy punch.  
10  
11 The tissue was fixed in 10% neutral buffered formalin overnight at room temperature. After  
12  
13 fixation, the tissue was washed with 70% ethanol and processed for histological analysis and H&E  
14  
15 staining. A pathologist was consulted in analysis of the samples.  
16  
17  
18  
19  
20  
21

## 22 **Statistical analysis**

23  
24 Data are expressed as mean  $\pm$  standard deviation, unless otherwise indicated, and N = 4 - 6  
25  
26 randomly assigned mice per time point and per group. These sample sizes were chosen based on  
27  
28 statistical power analysis and previous literature. Data were analyzed for statistical significance by  
29  
30 unpaired, two-tailed Student's t-tests.  
31  
32  
33

## 34 **Acknowledgements**

35  
36  
37 This work was supported in part by project funding provided by Sanofi, the Helmsley Charitable  
38  
39 Trust, and the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer  
40  
41 Institute. L.V. was supported by a NSF Graduate Research Fellowship. D.D. was supported by a  
42  
43 Marie Sklodowska Curie Fellowship. The authors acknowledge technical support from the Koch  
44  
45 Institute Swanson Biotechnology Center, specifically the Animal Imaging & Preclinical Testing  
46  
47 Core, the Histology Core, the High Throughput Screening Core, and the Nanotechnology Materials  
48  
49 Core. The authors would like to acknowledge Dong Soo Yun for assistance with cryo-TEM and  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Roderick Bronson for assistance with histological analysis, in addition to Suman Bose, Kevin J.  
4  
5 Kauffman, Owen S. Fenton, and Matthew J. Webber for helpful discussions.  
6  
7  
8  
9  
10

### 11 **Supporting Information Available**

12  
13 Supporting Information contains additional methods and supplemental Figures S1-S19, showing  
14  
15 polymer synthesis and characterization, nanoparticle characterization, additional *in vitro* protein  
16  
17 release and biocompatibility studies, nanoparticle migration *in vivo* through fluorescent imaging,  
18  
19 additional characterization of the inflammatory response, and supplemental blood glucose and  
20  
21 serum insulin levels of both healthy and diabetic mice. This material is available free of charge via  
22  
23 the Internet at <http://pubs.acs.org>.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


## References

1. Nathan, D. M. Long-Term Complications of Diabetes Mellitus. *N. Engl. J. Med.* **1993**, *328*, 1676-1685.
2. Giovannucci, E.; Harlan, D. M.; Archer, M. C.; Bergenstal, R. M.; Gapstur, S. M.; Habel, L. A.; Pollak, M.; Regensteiner, J. G.; Yee, D. Diabetes and Cancer: A Consensus Report. *CA Cancer J. Clin.* **2010**, *60*, 207-221.
3. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N. Engl. J. Med.* **1993**, *329*, 977-986.
4. Ohkubo, Y.; Kishikawa, H.; Araki, E.; Miyata, T.; Isami, S.; Motoyoshi, S.; Kojima, Y.; Furuyoshi, N.; Shichiri, M. Intensive Insulin Therapy Prevents the Progression of Diabetic Microvascular Complications in Japanese Patients with Non-Insulin-Dependent Diabetes Mellitus: A Randomized Prospective 6-Year Study. *Diabetes Res. Clin. Pract.* **1995**, *28*, 103-117.
5. Claxton, A. J.; Cramer, J.; Pierce, C. A Systematic Review of the Associations between Dose Regimens and Medication Compliance. *Clin. Ther.* **2001**, *23*, 1296-1310.
6. Peyrot, M.; Barnett, A.; Meneghini, L.; Schumm-Draeger, P. M., Insulin Adherence Behaviours and Barriers in the Multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. *Diabetic Med.* **2012**, *29*, 682-689.
7. Seaquist, E. R.; Miller, M. E.; Bonds, D. E.; Feinglos, M.; Goff, D. C.; Peterson, K.; Senior, P.; ACCORD Investigators. The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study. *Diabetes Care* **2012**, *35*, 409-414.
8. Cryer, P. E. Hypoglycemia, Functional Brain Failure, and Brain Death. *J. Clin. Invest.* **2007**, *117*, 868.
9. McCoy, R. G.; Van Houten, H. K.; Ziegenfuss, J. Y.; Shah, N. D.; Wermers, R. A.; Smith, S. A. Increased Mortality of Patients with Diabetes Reporting Severe Hypoglycemia. *Diabetes Care* **2012**, *35*, 1897-1901.
10. Siebenhofer, A. A.; Plank, J. J.; Berghold, A. A.; Narath, M. M.; Gfrerer, R. R.; Pieber, T. R. Short Acting Insulin Analogues *versus* Regular Human Insulin in Patients with Diabetes Mellitus. *Cochrane Database Syst. Rev.* **2004**, DOI: 10.1002/14651858.CD003287.pub3.
11. Peterson, G. E. Intermediate and Long-Acting Insulins: A Review of NPH Insulin, Insulin Glargine and Insulin Detemir. *Curr. Med. Res. Opin.* **2006**, *22*, 2613-2619.
12. Horvath, K.; Jeitler, K.; Berghold, A.; Ebrahim, S. H.; Gratzner, T. W.; Plank, J.; Kaiser, T.; Pieber, T. R.; Siebenhofer, A. Long-Acting Insulin Analogues *versus* NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus. *Cochrane Database Syst. Rev.* **2007**, DOI: 10.1002/14651858.CD005613.pub3.
13. Pickup, J.; Keen, H. Continuous Subcutaneous Insulin Infusion at 25 Years. *Diabetes Care* **2002**, *25*, 593-598.
14. Hovorka, R. Closed-Loop Insulin Delivery: From Bench to Clinical Practice. *Nat. Rev. Endocrinol.* **2011**, *7*, 385-395.
15. Gilligan, B. J.; Shults, M. C.; Rhodes, R. K.; Updike, S. J. Evaluation of a Subcutaneous Glucose Sensor out to 3 Months in a Dog Model. *Diabetes Care* **1994**, *17*, 882-887.
16. Wisniewski, N.; Moussy, F.; Reichert, W. Characterization of Implantable Biosensor Membrane Biofouling. *Fresenius' J. Anal. Chem.* **2000**, *366*, 611-621.
17. Bequette, B. W. Challenges and Recent Progress in the Development of a Closed-Loop Artificial Pancreas. *Annual Rev. Control* **2012**, *36*, 255-266.
18. Ravaine, V.; Ancla, C.; Catargi, B. Chemically Controlled Closed-Loop Insulin Delivery. *J. Controlled Release* **2008**, *132*, 2-11.
19. Veisoh, O.; Tang, B. C.; Whitehead, K. A.; Anderson, D. G.; Langer, R. Managing Diabetes with Nanomedicine: Challenges and Opportunities. *Nat. Rev. Drug Discovery* **2015**, *14*, 45-57.


- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Webber, M. J.; Anderson, D. G. Smart Approaches to Glucose-Responsive Drug Delivery. *J. Drug Targeting* **2015**, *23*, 651-655.
  21. Kost, J.; Horbett, T. A.; Ratner, B. D.; Singh, M. Glucose-Sensitive Membranes Containing Glucose Oxidase: Activity, Swelling, and Permeability Studies. *J. Biomed. Mater. Res., Part A* **1985**, *19*, 1117-1133.
  22. Podual, K.; Doyle, F.; Peppas, N. Preparation and Dynamic Response of Cationic Copolymer Hydrogels Containing Glucose Oxidase. *Polymer* **2000**, *41*, 3975-3983.
  23. Wu, W.; Mitra, N.; Yan, E. C.; Zhou, S. Multifunctional Hybrid Nanogel for Integration of Optical Glucose Sensing and Self-Regulated Insulin Release at Physiological pH. *ACS Nano* **2010**, *4*, 4831-4839.
  24. Kang, S. I.; Bae, Y. H. A Sulfonamide Based Glucose-Responsive Hydrogel with Covalently Immobilized Glucose Oxidase and Catalase. *J. Controlled Release* **2003**, *86*, 115-121.
  25. Gu, Z.; Aimetti, A. A.; Wang, Q.; Dang, T. T.; Zhang, Y.; Veiseh, O.; Cheng, H.; Langer, R.; Anderson, D. G. Injectable Nano-Network for Glucose-Mediated Insulin Delivery. *ACS Nano* **2013**, *7*, 4194-4201.
  26. Gu, Z.; Dang, T. T.; Ma, M.; Tang, B. C.; Cheng, H.; Jiang, S.; Dong, Y.; Zhang, Y.; Anderson, D. G. Glucose-Responsive Microgels Integrated with Enzyme Nanocapsules for Closed-Loop Insulin Delivery. *ACS Nano* **2013**, *7*, 6758-6766.
  27. Yu, J.; Zhang, Y.; Ye, Y.; DiSanto, R.; Sun, W.; Ranson, D.; Ligler, F. S.; Buse, J. B.; Gu, Z. Microneedle-Array Patches Loaded with Hypoxia-Sensitive Vesicles Provide Fast Glucose-Responsive Insulin Delivery. *Proc. Natl. Acad. Sci. U.S.A.* **2015**, *112*, 8260-8265.
  28. Hu, X.; Yu, J.; Qian, C.; Lu, Y.; Kahkoska, A. R.; Xie, Z.; Jing, X.; Buse, J. B.; Gu, Z. H<sub>2</sub>O<sub>2</sub>-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. *ACS Nano* **2017**, *11*, 613-620.
  29. Yu, J.; Qian, C.; Zhang, Y.; Cui, Z.; Zhu, Y.; Shen, Q.; Ligler, F. S.; Buse, J. B.; Gu, Z., Hypoxia and H<sub>2</sub>O<sub>2</sub> Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. *Nano Lett.* **2017**, *17*, 733-739.
  30. Bachelder, E. M.; Beaudette, T. T.; Broaders, K. E.; Dashe, J.; Fréchet, J. M. Acetal-Derivatized Dextran: An Acid-Responsive Biodegradable Material for Therapeutic Applications. *J. Am. Chem. Soc.* **2008**, *130*, 10494-10495.
  31. Broaders, K. E.; Cohen, J. A.; Beaudette, T. T.; Bachelder, E. M.; Fréchet, J. M. Acetalated Dextran is a Chemically and Biologically Tunable Material for Particulate Immunotherapy. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 5497-5502.
  32. Vegas, A. J.; Veiseh, O.; Doloff, J. C.; Ma, M.; Tam, H. H.; Bratlie, K.; Li, J.; Bader, A. R.; Langan, E.; Olejnik, K.; Fenton, P.; Kang, J. W.; Hollister-Locke, J.; Bochenek, M. A.; Chiu, A.; Siebert, S.; Tang, K.; Jhunjhunwala, S.; Aresta-Dasilva, S.; Dholakia, N. *et. al.* Combinatorial Hydrogel Library Enables Identification of Materials that Mitigate the Foreign Body Response in Primates. *Nat. Biotechnol.* **2016**, *34*, 345-345.
  33. Suarez, S.; Grover, G. N.; Braden, R. L.; Christman, K. L.; Almutairi, A. Tunable Protein Release from Acetalated Dextran Microparticles: A Platform for Delivery of Protein Therapeutics to the Heart Post-MI. *Biomacromolecules* **2013**, *14*, 3927-3935.
  34. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Larsen, U.; Ribel, U.; Markussen, J. Albumin Binding of Insulins Acylated with Fatty Acids: Characterization of the Ligand-Protein Interaction and Correlation between Binding Affinity and Timing of the Insulin Effect *In Vivo*. *Biochem. J.* **1995**, *312*, 725-731.
  35. Havelund, S.; Plum, A.; Ribel, U.; Jonassen, I.; Vølund, A.; Markussen, J.; Kurtzhals, P. The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin. *Pharm. Res.* **2004**, *21*, 1498-1504.
  36. Cramer, J. A.; Pugh, M. J. The Influence of Insulin Use on Glycemic Control: How Well Do Adults Follow Prescriptions for Insulin? *Diabetes Care* **2005**, *28*, 78-83.




- 1  
2  
3 37. Donnelly, L. A.; Morris, A. D.; Evans, J.; DARTS/MEMO Collaboration. Adherence to Insulin  
4 and its Association with Glycaemic Control in Patients with Type 2 Diabetes. *QJM Int. J. Med.*  
5 **2007**, *100*, 345-350.
- 6 38. Brod, M.; Rana, A.; Barnett, A. H. Adherence Patterns in Patients with Type 2 Diabetes on Basal  
7 Insulin Analogues: Missed, Mistimed and Reduced Doses. *Curr. Med. Res. Opin.* **2012**, *28*, 1933-  
8 1946.
- 9 39. Peyrot, M.; Barnett, A.; Meneghini, L.; Schumm-Draeger, P. M. Factors Associated with  
10 Injection Omission/Non-Adherence in the Global Attitudes of Patients and Physicians in Insulin  
11 Therapy Study. *Diabetes, Obes. Metab.* **2012**, *14*, 1081-1087.
- 12 40. Peyrot, M.; Rubin, R. R.; Kruger, D. F.; Travis, L. B. Correlates of Insulin Injection Omission.  
13 *Diabetes Care* **2010**, *33*, 240-245.
- 14 41. Ross, S. A.; Tildesley, H. D.; Ashkenas, J. Barriers to Effective Insulin Treatment: The  
15 Persistence of Poor Glycemic Control in Type 2 Diabetes. *Curr. Med. Res. Opin.* **2011**, *27*, 13-20.
- 16 42. Geller, A. I.; Shehab, N.; Lovegrove, M. C.; Kegler, S. R.; Weidenbach, K. N.; Ryan, G. J.;  
17 Budnitz, D. S. National Estimates of Insulin-Related Hypoglycemia and Errors Leading to  
18 Emergency Department Visits and Hospitalizations. *JAMA Intern. Med.* **2014**, *174*, 678-686.
- 19 43. Wang, H.-C.; Lee, A.-R. Recent Developments in Blood Glucose Sensors. *J. Food Drug Anal.*  
20 **2015**, *23*, 191-200.
- 21 44. Vashist, S. K.; Zheng, D.; Al-Rubeaan, K.; Luong, J. H.; Sheu, F.-S. Technology behind  
22 Commercial Devices for Blood Glucose Monitoring in Diabetes Management: A Review. *Anal.*  
23 *Chim. Acta* **2011**, *703*, 124-136.
- 24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 1.** Desired release kinetics can be achieved by altering the properties of nanoparticles. a) Schematic of release kinetics from rapid-release (high acyclic acetal content) and extended-release (high cyclic acetal content) Ac-dex nanoparticles. b) Rate of degradation of Ac-dex nanoparticles by percent cyclic modification as determined by concentration of soluble dextran in the supernatant. Nanoparticles were incubated in either acetate buffer (pH 4.7) or PBS (pH 7.4) at 37 °C with agitation. c) Schematic of glucose-responsive insulin release from acid-degradable Ac-dex nanoparticles. d) Average relative diameter of C55NPs in acetate buffer showing reduction in size over time. Inset: cryo-transmission electron micrograph of nanoparticles at time 0.




**Figure 2.** A co-formulation of 55% and 71% (% cyclic acetalation) Ac-dex nanoparticles have fast-acting and long-acting insulin release characteristics. a) Insulin release from C55NPs or C71NPs incubated in either acetate buffer (pH 4.7) or phosphate buffered saline (PBS, pH 7.4) at 37 °C with agitation. b) Glucose-mediated protein release from C55NPs or C71NPs (20 mg/mL) upon incubation in PBS, PBS + 100 mg/dL glucose, or PBS + 400 mg/dL glucose at 37 °C with agitation. c) Two regimes of protein release resulting from the addition of acid (HCl) to a mixture of C55NPs and C71NPs after 24 hours of incubation. d) Glucose-mediated protein release from a mixture of C55NPs and C71NPs (20 mg/mL). e) Circular dichroism of released insulin after incubating NPs with 0.025% trypsin-EDTA for 24 hours compared to unprocessed fresh insulin confirming retention of secondary structure. f) EC<sub>50</sub> determined by AKT phosphorylation of C2C12 cells exposed to fresh insulin or insulin released from nanoparticles after various incubation times. NS:  $p > 0.05$ .




**Figure 3.** NP-treated mice show limited systemic pro-inflammatory cytokine response at 6 and 24 h with no prolonged local inflammatory response at 28 d according to histological analysis. Serum concentration of pro-inflammatory cytokines 6 and 24 h following administration of PBS, 2 mg/kg lipopolysaccharide (LPS), 5 mg/kg empty NPs, or 5 mg/kg NPs encapsulating insulin and enzymes in addition to naïve mice. Analyzed cytokines include a) IL-1 $\beta$ , b) IL-12, c) IL-6, and d) TNF- $\alpha$ . Values below the standard curve are reported as less than or equal the limit of detection of the ELISA. Data represent mean  $\pm$  standard error of the mean; N = 5. Statistical significance is indicated by \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001 in comparison to PBS. H&E-stained histological images of 5 mm skin biopsies surrounding the injection site of e) 5 mg/kg empty NPs or f) PBS after 28 d. Representative images of 5 biological replicates.



**Figure 4.** Doses between 5 and 14 IU/kg insulin in co-formulated Ac-dex NPs show effective glycemic control in diabetic mice with limited risk of hypoglycemia in healthy mice. a) Blood glucose levels of streptozotocin-induced type 1 diabetic mice following administration of empty NPs, 3 IU/kg naked insulin, or 14.4 IU/kg insulin in Ac-dex NPs. Arrows represent intraperitoneal glucose tolerance tests (GTTs, 1.5 g/kg) every 3 h. b) Area under the curve for the first 9 hours of (a) in addition to doses of 3, 5, and 9 IU/kg NPs. c) Blood glucose levels of healthy mice following administration of empty NPs, 3 IU/kg naked insulin, or 14.4 IU/kg insulin in Ac-dex NPs. d) The hypoglycemic effect calculated as the area above the curve of (c) for the first 2.5 h in addition to doses of 5, 9, and 25 IU/kg NPs. Data represent mean  $\pm$  standard deviation (a,c) or standard error of the mean (b,d). Statistical significance is indicated by \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ . NS:  $p > 0.05$ .



**Figure 5.** Glucose-responsive NPs provide similar blood glucose profiles after 0, 1, or 2 GTTs and enhance glycemic control relative to constituent components and free long-acting or native insulin. a) Blood glucose levels of diabetic mice following administration of 9 IU/kg NPs with 0, 1 (1.5 g/kg at 3 h), or 2 GTTs (1.5 g/kg at 3 h, 2 g/kg at 6 h). b) Area under the curve for (a). c) Response of diabetic mice to a GTT (3 g/kg) following injection of 9 IU/kg NPs, 9 IU/kg NPs(- Enzymes), or an equivalent dose of NPs(- Insulin). d) Area under the curve for (c). e) Blood glucose levels of diabetic mice following administration of 5 IU/kg NPs, long-acting insulin, or naked insulin with GTTs at 3 h and 6 h (1.5 g/kg). f) Area under the curve for (e) by 3 h time interval. Shaded regions and error bars represent standard error of the mean. Statistical significance is indicated by \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p \leq 0.0001$  in comparison to NPs.



**Figure 6.** Co-formulated Ac-dex NPs show glucose-responsive insulin release *in vivo*. a) Serum human insulin levels of healthy mice 1 h after administration or 2 h after administration with a GTT after 1 h (3 g/kg). b) Serum human insulin of diabetic mice following injection of NPs with a GTT at 6 hours (2 g/kg). c) Serum human insulin of healthy mice (1 h post-GTT) or diabetic mice (1 h post-administration) receiving NPs(- Enzymes) or NPs. Data represent mean  $\pm$  standard error of the mean (a,c) or standard deviation (b). Values below the standard curve are reported as less than or equal to 3  $\mu$ IU/mL, the limit of detection of the ELISA. Statistical significance is indicated by  $**p < 0.01$ . NS:  $p > 0.05$ .

For Table of Contents Only

